SYS-CON MEDIA Authors: Gilad Parann-Nissany, RealWire News Distribution

News Feed Item

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Eisai's Aricept (donepezil hydrochloride) is a piperidine derivative that acts centrally as a reversible AChEI. Aricept is approved at the strengths of 5, 10, and 23mg and is indicated for the treatment of mild to severe Alzheimer's dementia. As a member of the AChEI class, donepezil can only provide symptomatic relief and cannot modify the underlying disease progression.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.2 Symptoms 27
4 Disease Management 29
4.1 Diagnosis 29
4.1.1 Probable Alzheimer's Disease Dementia 30
4.1.2 Possible AD Dementia 31
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31
4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 32
4.1.5 Preclinical AD 32
4.1.6 Mild Cognitive Impairment 33
4.2 Treatment Overview 35
5 Competitive Assessment 38
5.1 Overview 38
5.2 Strategic Competitor Assessment 38
6 Aricept (donepezil hydrochloride) 41
6.1 Overview 41
6.2 Efficacy 43
6.3 Safety 44

6.4 SWOT Analysis 45
6.5 Forecast 45
7 Appendix 47
7.1 Bibliography 47
7.2 Abbreviations 65
7.3 Methodology 72
7.4 Forecasting Methodology 72
7.4.1 Diagnosed AD patients 73
7.4.2 Percent Drug-treated Patients 74
7.4.3 General Pricing Assumptions 74
7.4.4 Individual Drug Assumptions 76
7.4.5 Generic Erosion 76
7.5 Physicians and Specialists Included in this Study 77
7.6 About the Authors 78
7.6.1 Author 78
7.6.2 Global Head of Healthcare 79
7.7 About GlobalData 80
7.8 Disclaimer 80

List of Tables

Table 1:Symptoms of AD 28
Table 2:Guidelines for the Treatment of AD 35
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36
Table 4:Leading Branded Treatments for AD, 2013 39
Table 5:Product Profile – Aricept 42
Table 6:Aricept SWOT Analysis, 2013 45
Table 7:Global Sales Forecasts ($m) for Aricept, 2012–2022 46

List of Figures

Figure 1:Atrophy of the Brain in AD 17
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 19
Figure 3:Non-Amyloidogenic Metabolism of APP 21
Figure 4:Amyloidogenic Metabolism of APP 22
Figure 5:Neurofibrillary Tangles 24
Figure 6:Oxidative Damage Due to Free Radicals 26
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 40

Read the full report:
Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022
http://www.reportbuyer.com/pharma_healthcare/diseases/aricept_alzheimers_disease_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.